Share-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the nine months ended March 31, 2018 is as follows:

	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2017		8.0		$	24.67
Options granted		—		$	—
Less:
Options exercised		(1.0	)	$	24.99
Options canceled or expired		—		$	—
Options outstanding at March 31, 2018		7.0		$	24.62
Options exercisable at March 31, 2018		7.0		$	24.62

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the nine months ended March 31, 2018 is as follows:

	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2017		2.0		$	33.02
RSUs granted		1.1		$	32.68
Less:
RSUs vested		(0.7	)	$	30.33
RSUs canceled		(0.2	)	$	28.35
RSUs outstanding at March 31, 2018		2.2		$	31.16

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:

	Three months ended				Nine months ended
	March 31,				March 31,
	2018		2017		2018		2017
Cost of molecular diagnostic testing	$	0.2	$	0.2	$	0.5	$	0.7
Cost of pharmaceutical and clinical services		0.1		0.1		0.2		0.2
Research and development expense		1.0		1.4		3.1		4.3
Selling, general, and administrative expense		5.3		5.8		16.2		17.5
Total share-based compensation expense	$	6.6	$	7.5	$	20.0	$	22.7